Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTUN7MC)

DTT Name T-cell surface glycoprotein CD3 (CD3)
Synonyms Cluster of differentiation 3
Gene Name CD3
DTT Type
Successful target
 [1]
UniProt ID
NOUNIPROTAC
TTD ID
T60345

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
7 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [1]
Elranatamab DMG1MW2 Multiple myeloma 2A83 Approved [2]
Epcoritamab DMEX86V Diffuse large B-cell lymphoma 2A81 Approved [3]
Glofitamab DM45HT6 Diffuse large B-cell lymphoma 2A81 Approved [4]
Mosunetuzumab DM15ZIB Follicular lymphoma 2A80 Approved [5]
Talquetamab DMXRENI Multiple myeloma 2A83 Approved [6]
Teplizumab DMZ3P6C Type-1 diabetes 5A10 Approved [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Approved Drug(s)
57 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Nivatrotamab DMAOUZV Small-cell lung cancer 2C25.Y Phase 2 [8]
Odronextamab DMP6NVV B-cell non-hodgkin lymphoma 2B33.5 Phase 2 [9]
Otelixizumab DMFNDBC Type-1 diabetes 5A10 Phase 2 [10]
Plamotamab DMOV28A Diffuse large B-cell lymphoma 2A81 Phase 2 [11]
TAK-280 DM08RE5 Aggressive cancer 2A00-2F9Z Phase 2 [12]
Tarlatamab DME33OU Small-cell lung cancer 2C25.Y Phase 2 [13]
Acapatamab DMTAI2F Prostate cancer 2C82.0 Phase 1/2 [14]
GEN3013 DMZABYH Diffuse large B-cell lymphoma 2A81 Phase 1/2 [15]
ISB 1302 DM1WD8F HER2-positive breast cancer 2C60-2C65 Phase 1/2 [16]
ISB 1342 DMG107N Multiple myeloma 2A83 Phase 1/2 [16]
REGN4018 DM7LOSK Ovarian cancer 2C73 Phase 1/2 [17]
REGN4336 DMAKSZW Prostate cancer 2C82.0 Phase 1/2 [18]
REGN5458 DMAGX0Q Multiple myeloma 2A83 Phase 1/2 [19]
REGN5459 DMRE0LU Multiple myeloma 2A83 Phase 1/2 [20]
SAR440234 DM6M8O4 Acute myeloid leukaemia 2A60 Phase 1/2 [21]
A-337 DMRWTFG Non-small-cell lung cancer 2C25.Y Phase 1 [21]
ABBV-184 DM71Q69 Acute myeloid leukaemia 2A60 Phase 1 [22]
AFM11 DMIFJZD B-cell non-hodgkin lymphoma 2B33.5 Phase 1 [23]
AMG 160 DMM0HNF Non-small-cell lung cancer 2C25 Phase 1 [24]
AMG 199 DMWG2K6 Esophagogastric junction neoplasm 2B71 Phase 1 [24]
AMG 330 DMC3G2E Acute myeloid leukaemia 2A60 Phase 1 [25]
AMG 340 DM3VRX6 Prostate cancer 2C82.0 Phase 1 [26]
AMG 424 DMLAP8F Multiple myeloma 2A83 Phase 1 [24]
AMG 427 DMI7JO6 Acute myeloid leukaemia 2A60 Phase 1 [24]
AMG 596 DM4G1SP Glioblastoma multiforme 2A00.0 Phase 1 [24]
AMG 673 DMA3B9T Acute myeloid leukaemia 2A60 Phase 1 [24]
AMG 701 DM6IT3M Multiple myeloma 2A83 Phase 1 [24]
AMG 757 DMLYP2N Neuroendocrine cancer 2B72.1 Phase 1 [24]
AMG 910 DMCG7XL Esophagogastric junction neoplasm 2B71 Phase 1 [24]
APVO436 DMUAMZY Acute myeloid leukaemia 2A60 Phase 1 [27]
ASP2138 DM96QLF Stomach cancer 2B72 Phase 1 [28]
CCW702 DMPTYE6 Prostate cancer 2C82.0 Phase 1 [29]
CD20Bi aATC DMGXS8L Non-hodgkin lymphoma 2B33.5 Phase 1 [30]
CX-904 DMOOHDN Colorectal cancer 2B91.Z Phase 1 [31]
GBR1302 DM52O7W Solid tumour/cancer 2A00-2F9Z Phase 1 [32]
GEM333 DMDMKVL Acute myeloid leukaemia 2A60 Phase 1 [33]
GEN1044 DMQ9317 Solid tumour/cancer 2A00-2F9Z Phase 1 [34]
IGM-2323 DMMPINS Non-hodgkin lymphoma 2B33.5 Phase 1 [35]
JNJ-63709178 DM5SZAK Acute myeloid leukaemia 2A60 Phase 1 [36]
JNJ-75348780 DMSDSFX Chronic lymphocytic leukaemia 2A82.0 Phase 1 [37]
JNJ-78278343 DM27FAN Prostate cancer 2C82.0 Phase 1 [38]
M802 DM132EG Solid tumour/cancer 2A00-2F9Z Phase 1 [39]
MGD006 DMQB4VN Acute lymphoblastic leukaemia 2A85 Phase 1 [40]
MGD014 DMZN5QX Human immunodeficiency virus-1 infection 1C62 Phase 1 [41]
PF-07062119 DME3BJL Solid tumour/cancer 2A00-2F9Z Phase 1 [42]
PF-07260437 DMU7LYP Breast cancer 2C60-2C65 Phase 1 [43]
RG6007 DMLGQJR Acute myeloid leukaemia 2A60 Phase 1 [44]
RG6156 DMPKZX7 Glioblastoma 2A00 Phase 1 [44]
RG6234 DMYUSOJ Multiple myeloma 2A83 Phase 1 [44]
RG6524 DMT22UV Aggressive cancer 2A00-2F9Z Phase 1 [44]
Runimotamab DML6BK5 Breast cancer 2C60-2C65 Phase 1 [45]
SAR442257 DMXD5QP Malignant neoplasm 2A00-2F9Z Phase 1 [46]
SAR443216 DMUQNG6 Gastric cancer 2B72 Phase 1 [47]
Tepoditamab DMC84Y9 Acute myelogenous leukaemia 2A41 Phase 1 [48]
TNB-383B DMAI0SH Multiple myeloma 2A83 Phase 1 [49]
TNB-486 DMSRICG B-cell lymphoma 2A86 Phase 1 [50]
WVT078 DM7MS10 Multiple myeloma 2A83 Phase 1 [51]
------------------------------------------------------------------------------------
⏷ Show the Full List of 57 Clinical Trial Drug(s)
1 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IM1240 DMTV0DK Aggressive cancer 2A00-2F9Z Preclinical [52]
------------------------------------------------------------------------------------

References

1 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761345
3 Clinical pipeline report, company report or official report of Genmab.
4 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761309
5 Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling. NPJ Syst Biol Appl. 2020 Aug 28;6(1):28.
6 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761342
7 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
8 Clinical pipeline report, company report or official report of Y-mAbs Therapeutics.
9 Odronextamab, a human CD20*CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022 May;9(5):e327-e339.
10 Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.Diabetes Care.2014 Oct;37(10):2746-54.
11 Plamotamab (XmAb(?)13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenstr?m macroglobulinemia. Leuk Lymphoma. 2022 Mar;63(3):738-742.
12 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
13 Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study. J Clin Oncol. 2023 Jun 1;41(16):2893-2903.
14 The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer. Clin Cancer Res. 2021 May 15;27(10):2928-2937.
15 DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625.
16 Clinical pipeline report, company report or official report of Ichnos Sciences.
17 A Mucin 16 bispecific T cell-engaging antibody for the treatment of ovarian cancer. Sci Transl Med. 2019 Jun 19;11(497):eaau7534.
18 ClinicalTrials.gov (NCT05125016) Phase 1/2 Study of REGN4336 (a PSMAXCD3 Bispecific Antibody) Administered Alone or in Combination With Cemiplimab in Patients With Metastatic Castration-Resistant Prostate Cancer. U.S.National Institutes of Health.
19 A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells. Blood Adv. 2021 Mar 9;5(5):1291-1304.
20 Clinical pipeline report, company report or official report of Regeneron Pharmaceuticals.
21 Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019 Aug;18(8):585-608.
22 Clinical pipeline report, company report or official report of AbbVie.
23 A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584-604.
24 Clinical pipeline report, company report or official report of Amgen.
25 Preclinical characterization of AMG 330, a CD3/CD33-bispecific T-cell-engaging antibody with potential for treatment of acute myelogenous leukemia. Mol Cancer Ther. 2014 Jun;13(6):1549-57.
26 ClinicalTrials.gov (NCT04740034) A Multicenter, Phase 1, Open-label, Dose-escalation and Expansion Study of AMG 340, a Bispecific Antibody Targeting PSMA in Subjects With Metastatic Castrate-Resistant Prostate Carcinoma. U.S.National Institutes of Health.
27 Clinical pipeline report, company report or official report of Aptevo.
28 ClinicalTrials.gov (NCT05365581) A Phase 1/1b Study of ASP2138 in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma or Metastatic Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression. U.S.National Institutes of Health.
29 Clinical pipeline report, company report or official report of AbbVie.
30 CD20-Targeted T Cells after Stem Cell Transplantation for High Risk and Refractory Non-Hodgkin's Lymphoma. Biol Blood Marrow Transplant. 2013 June; 19(6): 925-933.
31 Clinical pipeline report, company report or official report of CytomX
32 Clinical pipeline report, company report or official report of Glenmark Pharmaceuticals.
33 Clinical pipeline report, company report or official report of Gemoab.
34 Clinical pipeline report, company report or official report of AbbVie.
35 Clinical pipeline report, company report or official report of IGM Biosciences.
36 Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol. 2018 Mar;25(2):136-145.
37 ClinicalTrials.gov (NCT04540796) A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants With NHL and CLL. U.S.National Institutes of Health.
38 ClinicalTrials.gov (NCT04898634) A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer. U.S.National Institutes of Health.
39 A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells. J Exp Clin Cancer Res. 2019 Aug 14;38(1):355.
40 A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
41 Clinical pipeline report, company report or official report of MacroGenics.
42 Discovery and optimization of a novel anti-GUCY2c x CD3 bispecific antibody for the treatment of solid tumors. MAbs. Jan-Dec 2021;13(1):1850395.
43 ClinicalTrials.gov (NCT05067972) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07260437 IN ADVANCED OR METASTATIC SOLID TUMORS. U.S.National Institutes of Health.
44 Clinical pipeline report, company report or official report of Roche
45 ClinicalTrials.gov (NCT03448042) A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers. U.S. National Institutes of Health.
46 Clinical pipeline report, company report or official report of Sanofi.
47 Clinical pipeline report, company report or official report of Sanofi
48 MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther. 2019 Jul;19(7):721-733.
49 Clinical pipeline report, company report or official report of AbbVie.
50 Clinical pipeline report, company report or official report of Teneobio.
51 ClinicalTrials.gov (NCT04123418) A Study of WVT078 in Patients With Multiple Myeloma (MM). U.S. National Institutes of Health.
52 Clinical pipeline report, company report or official report of Purple